Session

Ongoing prospective trials

Poster Session 16

  • Location:
    Room Vienna, North Hall (Level 1)
  • Chairs:
     J. Bellmunt, Barcelona (ES)
     M. Retz, Munich (DE)
     S. Shariat, Vienna (AT)
  • Aims and objectives of this session

    To show what is currently going on in oncologic urology and other fields in urology regarding multicentre prospective randomized studies.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
Overview on systematic reviews/meta analysis
 S. Shariat, Vienna (AT)
206
A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS)

By: Smith M.1, Saad F.2, Hussain M.3, Sternberg C.4, Fizazi K.5, Crawford D.6, Yamada K.7, Kappeler C.8, Kuss I.8, Tombal B.9

Institutes: 1Massachusetts General Hospital Cancer Center and Harvard Medical School, Dept. of Urologic Oncology, Boston, United States of America, 2University of Montreal, University of Montreal Hospital Center/CRCHUM, Montreal, Canada, 3Northwestern University Feinberg School of Medicine, Dept. of Hematology/Oncology, Chicago, United States of America, 4San Camillo and Forlanini Hospitals, Dept. of Medical Oncology, Rome, Italy, 5Gustave Roussy, University of Paris Sud, Cancer Medicine, Villejuif, France, 6University of Colorado, Dept. of Urologic Oncology, Aurora, United States of America, 7Bayer Pharmaceuticals, Dept. of Oncology, Whippany, United States of America, 8Bayer Pharma AG, Dept. of Oncology, Berlin, Germany, 9Cancer Centre, Catholic University of Louvain (UCL), Dept. of Urology, Brussels, Belgium

207
Prostate cancer intra-tumoral heterogeneity: Correlation between clinical parameters, mpMRI and biomarkers

By: Carmona Echeverria L.M.1, Johnston E.2, Shanmugabavan Y.3, Rowan A.4, Goh G.5, Scott R.3, Hung M.3, Gelinger M.6, Arya M.3, Emberton M.3, Freeman A.7, Punwani S.2, Barrat D.8, Yipeng H.8, Attard G.9, Whitaker H.1, Linch M.5, De Bono J.9, Swanston C.4, Ahmed H.3

Institutes: 1University College London, Dept. of Surgery and Interventional Science – Centre For Molecular Intervention, London, United Kingdom, 2University College London, UCL Centre For Medical Imaging, London, United Kingdom, 3University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, 4Cancer Research UK, Translational Cancer Therapeutics Laboratory, London, United Kingdom, 5University College London, Cancer Institute, London, United Kingdom, 6Institute of Cancer Research, Centre For Evolution and Cancer, London, United Kingdom, 7University College London, Dept. of Research Pathology, London, United Kingdom, 8University College London, UCL Centre For Medical Image Computing, London, United Kingdom, 9Institute of Cancer Research, Dept. of Clinical Studies, London, United Kingdom

208
KEYNOTE-365: Phase 1b/2 trial of pembrolizumab combination therapy for metastatic castration-resistant prostate cancer (mCRPC)

By: Yu E.Y.2, Wu H.1, Schloss C.1

Institutes: 1Merck & Co., Inc., Dept. of Clinical Oncology, Kenilworth, United States of America, 2Seattle Cancer Care Alliance, Dept. of Medicine, Seattle, United States of America

209
Multi-institutional validation and assessment of training modalities in robotic surgery (the MARS project)

By: Raison N.1, Ahmed K.1, Aydin A.2, Van Der Poel H.3, Mottrie A.4, Dasgupta P.2

Institutes: 1King’s College London, Mrc Centre For Transplantation, London, United Kingdom, 2King’s College London, MRC Centre For Transplantation, London, United Kingdom, 3Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, 4OLV Clinic, Dept. of Urology, Aalst, Belgium

210
The effects of the human fetal estrogen estetrol (E4) in healthy men to estimate its potential use for the treatment of prostate cancer

By: Dutman E., Zimmerman Y., Coelingh-Bennink H.

Institutes: Pantarhei Oncology BV, Zeist, The Netherlands

211
PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

By: Necchi A.1, Mariani L.2, Anichini A.3, Giannatempo P.1, Raggi D.1, Togliardi E.4, Calareso G.5, Nicolai N.6, Crippa F.7, Biasoni D.6, Torelli T.6, Catanzaro M.6, Stagni S.6, Piva L.6, Salvioni R.6

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pharmacy Unit, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 7Fondazione IRCCS – Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy

212
IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC)

By: Gschwend J.1, Bellmunt J.2, Castellano D.3, Daneshmand S.4, Hussain M.5, Nishiyama H.6, Powles T.7, Degaonkar V.8, Nguyen Duc A.9, Culine S.10

Institutes: 1Technical University of Munich, Dept. of Urology, Munich, Germany, 2Bladder Cancer Center, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, United States of America, 3Hospital Universitario 12 De Octubre, Dept. of Oncology, Madrid, Spain, 4University of Southern California, Dept. of Oncology, Los Angeles, United States of America, 5Northwestern University, Dept. of Oncology, Chicago, United States of America, 6University of Tsukuba, Dept. of Oncology, Ibaraki, Japan, 7Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, 8Genentech, Inc., Dept. of Oncology, South San Francisco, United States of America, 9Roche, Dept. of Oncology, Basel, Switzerland, 10Hôpital Saint-Louis, Dept. of Oncology, Paris, France

213
Phase 3 randomized trial of intravenous mannitol versus placebo prior to renal ischemia during partial nephrectomy: Impact on renal functional outcomes

By: Spaliviero M., Power N., Murray K., Sjoberg D., Benfante N., Bernstein M., Wren J., Russo P., Coleman J.

Institutes: Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America

214
A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma

By: Hutson T.1, Xing D.2, Dutcus C.2, Baig M.3, Fishman M.4

Institutes: 1Texas Oncology, Dallas, United States of America, 2Eisai, Woodcliff Lake, United States of America, 3Eisai, OBG, Woodcliff Lake, United States of America, 4H. Lee Moffitt, Cancer and Research Center, Tampa, United States of America

215
A national, prospective, non-interventional study (NIS) of nivolumab (BMS-936558) in patients with advanced renal cell carcinoma after prior therapy

By: Grimm M-O., Grünwald V., Bedke J.

Institutes: Jena University Hospital, Dept. of Urology, Jena, Germany

216
APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

By: Necchi A.1, Mariani L.2, Anichini A.3, Giannatempo P.1, Raggi D.1, Togliardi E.4, Calareso G.5, Nicolai N.6, Crippa F.7, Salvioni R.6

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 7Fondazione IRCCS – Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy

217
An effective and acceptable cleaning method for re-use of catheters for intermittent catheterisation (IC)

By: Wilks S.1, Morris N.2, Delgado D.2, Prieto J.1, Moore K.3, Macaulay M.4, Fader M.1

Institutes: 1University of Southampton, Dept. of Health Sciences, Southampton, United Kingdom, 2Bristol Urological Institute, Dept. of Learning and Research, Bristol, United Kingdom, 3University of Alberta, Faculty of Nursing, Alberta, Canada, 4University College London, Continence & Skin Technology Group, London, United Kingdom

Summary
 J. Bellmunt